Literature DB >> 3434218

Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients.

D W Dickson1, P Davies, R Mayeux, H Crystal, D S Horoupian, A Thompson, J E Goldman.   

Abstract

Post-mortem pathological and biochemical studies are reported on six patients with progressive dementia. The characteristic pathological finding was neurofilament-containing cytoplasmic inclusions in cortical and subcortical neurons. The clinical and pathological findings were consistent with so-called diffuse Lewy body disease. The patients had variable changes of the Alzheimer type, with five of six patients displaying "plaques only" Alzheimer's changes. Biochemical studies showed profound decreases in neocortical choline acetyltransferase (ChAT) activities that correlated with marked neuronal loss in the basal nucleus of Meynert. ChAT activities were normal in the hippocampus in three patients who also had no significant Alzheimer type hippocampal changes. All patients had decreased cortical somatostatin-like immunoreactivity. Our observations suggest that dementia in diffuse Lewy body disease bears biochemical similarities to Alzheimer's disease, in that biochemical markers for both intrinsic cortical neurons and ascending cholinergic neurons are affected.

Entities:  

Mesh:

Year:  1987        PMID: 3434218     DOI: 10.1007/BF00686786

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  36 in total

1.  Two monoclonal antibodies recognize Alzheimer's neurofibrillary tangles, neurofilament, and microtubule-associated proteins.

Authors:  H Ksiezak-Reding; S H Yen
Journal:  J Neurochem       Date:  1987-02       Impact factor: 5.372

2.  Parkinson's disease in patients with Alzheimer's disease.

Authors:  J Leverenz; S M Sumi
Journal:  Arch Neurol       Date:  1986-07

3.  Dementia and Parkinson's disease associated with diffuse cortical Lewy bodies.

Authors:  E J Byrne; J Lowe; R B Godwin-Austen; T Arie; R Jones
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.

Authors:  I Nakano; A Hirano
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

6.  Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.

Authors:  M F Beal; M F Mazurek; C N Svendsen; E D Bird; J B Martin
Journal:  Ann Neurol       Date:  1986-10       Impact factor: 10.422

7.  Basal forebrain neurons in the dementia of Parkinson disease.

Authors:  P J Whitehouse; J C Hedreen; C L White; D L Price
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

Review 8.  The nucleus basalis of Meynert.

Authors:  C Ezrin-Waters; L Resch
Journal:  Can J Neurol Sci       Date:  1986-02       Impact factor: 2.104

9.  Pathologic correlates of dementia in Parkinson's disease.

Authors:  H C Chui; J A Mortimer; U Slager; C Zarow; W Bondareff; D D Webster
Journal:  Arch Neurol       Date:  1986-10

10.  Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes.

Authors:  D W Dickson; S H Yen; K I Suzuki; P Davies; J H Garcia; A Hirano
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

View more
  28 in total

1.  Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies.

Authors:  Brittany N Dugger; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2010-08-19       Impact factor: 17.088

2.  Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease.

Authors:  G Lennox; J Lowe; K Morrell; M Landon; R J Mayer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

3.  Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

Authors:  G Lennox; J Lowe; M Landon; E J Byrne; R J Mayer; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

Review 4.  Diffuse Lewy body disease in Japan.

Authors:  K Kosaka
Journal:  J Neurol       Date:  1990-06       Impact factor: 4.849

5.  Cortical Lewy body dementia: clinical features and classification.

Authors:  W R Gibb; P J Luthert; I Janota; P L Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.

Authors:  T Iwatsubo; H Yamaguchi; M Fujimuro; H Yokosawa; Y Ihara; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

7.  Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease.

Authors:  R Nardone; A Bratti; F Tezzon
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 8.  Probing modifications of the neuronal cytoskeleton.

Authors:  L C Doering
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

9.  Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases.

Authors:  K K Gnanalingham; E J Byrne; A Thornton; M A Sambrook; P Bannister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

10.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.